Ligand Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Ligand Pharma (LGND) Tops Q2 EPS by 29c
July 29, 2021 4:09 PM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.63, $0.29 better than the analyst estimate of $1.34. Revenue for the quarter came in at $54.7 million versus the consensus estimate of $70.41 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
... More